![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
12 min
![](/assets/artwork/1x1-42817eea7ade52607a760cbee00d1495.gif)
Peter Sandercock and IST-3 Peter Sandercock and IST-3
-
- Sciences
Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.
Acute ischemic stroke is a major public health burden and globally a common cause of death and disability. Intravenous recombinant tissue plasminogen activator (rt-PA) is approved for use in selected patients with ischemic stroke within 3 hours of symptom onset. The International Stroke Trial or IST-3 seeks to determine whether a wider range of patients may benefit the International Journal of Stroke spoke to chief investigator Dr Peter Sandercock.
12 min